<DOC>
	<DOCNO>NCT02314819</DOCNO>
	<brief_summary>Fruquintinib administer 5mg daily ( QD ) 4 week treatment cycle ( three week one week ) well tolerate demonstrate encouraging preliminary clinical antitumor activity patient metastatic colorectal cancer ( CRC ) phase Ib phase 2 study . This study aim evaluate efficacy safety Fruquintinib treatment patient metastatic CRC progress second line standard chemotherapy</brief_summary>
	<brief_title>A Phase III Trial Evaluating Fruquintinib Efficacy Safety 3+ Line Colorectal Cancer Patients （FRESCO )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter Phase III clinical trial compare efficacy safety Fruquintinib plus BSC versus placebo plus BSC patient metastatic colorectal cancer progress second-line standard chemotherapy . After check eligibility criterion , subject randomize Fruquintinib plus BSC group ( treatment group ) placebo plus BSC group ( control group ) ration 2:1 . Primary Efficacy Endpoint : Overall Survival ( OS ) . Secondary Efficacy Endpoints : Progression free survival ( PFS ) ( According RECIST Version 1.1 ) , Objective Response Rate ( ORR ) , Disease Control Rate ( DCR ) , . Safety tolerance evaluate incidence , severity outcome AEs categorize severity accordance NCI CTC AE Version 4.0 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>≥ 18 ≤ 75 year age , ≥ 40Kg Histological cytological confirm colorectal cancer ECOG performance status 01 Standard regimen fail standard regimen available Adequate hepatic , renal , heart , hematologic function At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Signed date informed consent Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Pregnant lactate woman Any factor influence usage oral administration Evidence CNS metastasis Intercurrence one following : noncontrolled hypertension , coronary artery disease , arrhythmia heart failure Abuse alcohol drug Less 4 week last clinical trial Previous treatment VEGFR inhibition Disability serious uncontrolled intercurrence infection Proteinuria ≥ 2+ ( 1.0g/24hr ) Have evidence history bleeding tendency within two month enrollment , regardless seriousness Within 12 month first treatment occur artery/venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) etc . Within 6 month first treatment occur acute myocardial infarction , acute coronary syndrome CABG Bone fracture wound cure long time Coagulation dysfunction , hemorrhagic tendency receive anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>colorectal cancer</keyword>
</DOC>